

Phage Therapy of Local and Systemic Disease Caused by *Vibrio vulnificus* in Iron-Dextran-Treated Mice

Karen E. Cervený,¹ Angelo DePaola,² Donna H. Duckworth,¹ and Paul A. Gulig^{1*}

Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, Florida 32610,¹ and Gulf Coast Seafood Laboratory, U.S. Food and Drug Administration, Dauphin Island, Alabama 36528²

Received 28 January 2002/Returned for modification 29 March 2002/Accepted 29 July 2002

Vibrio vulnificus is a gram-negative bacterium that contaminates filter-feeding shellfish such as oysters. After ingestion of contaminated oysters, predisposed people may experience highly lethal septicemia. Contamination of wounds with the bacteria can result in devastating necrotizing fasciitis, which can progress to septicemia. The extremely rapid progression of these diseases can render antibiotic treatment ineffective, and death is a frequent outcome. In this study, we examined the potential use of bacteriophages as therapeutic agents against *V. vulnificus* in an iron-dextran-treated mouse model of *V. vulnificus* infection. Mice were injected subcutaneously with 10 times the lethal dose of *V. vulnificus* and injected intravenously, either simultaneously or at various times after infection, with phages. Treatment of mice with phages could prevent death; systemic disease, as measured by CFU per gram of liver and body temperature; and local disease, as measured by CFU per gram of lesion material and histopathologic analysis. Two different phages were effective against three different *V. vulnificus* strains with various degrees of virulence, while a third phage that required the presence of seawater to lyse bacteria *in vitro* was ineffective at treating mice. Optimum protection required that the phages be administered within 3 h of bacterial inoculation at doses as high as 10⁸ PFU. One of the protective phages had a half-life in blood of over 2 h. These results demonstrate that bacteriophages have therapeutic potential for both localized and systemic infections caused by *V. vulnificus* in animals. This model should be useful in answering basic questions regarding phage therapy.

Although research regarding the therapeutic use of bacteriophages has gone on without interruption since 1926 in Eastern Europe, this field of study has been, until very recently, somewhat neglected in the West (for reviews, see references 10 and 39). Within the past two decades, however, there has been a renewed interest in phage therapy due primarily to the increasing incidence of antibiotic-resistant bacteria and the lack of development of new types of antibiotics to control infections caused by these antibiotic-resistant organisms. The efficacy of phages in treating bacterial disease has been demonstrated by using animal models for *Escherichia coli* (21, 31–34), *Salmonella enterica* serovar Typhimurium (2), and *Pseudomonas aeruginosa* (35, 36). Phages have also been used successfully to prevent bacterial disease in fish (26) and to control pathogens of tomatoes (12). Although it is unlikely that phages will ever replace antibiotics, they may be of some use when no effective antibiotics are available or in conjunction with antibiotics for better treatment of disease. To examine the potential usefulness of phages, either alone or in conjunction with antibiotics, phages will have to be studied in a variety of animal models against bacteria with different mechanisms of virulence. To contribute to this understanding of where and how phage therapy may be appropriate, we have begun studying the therapeutic effect of phages against *V. vulnificus*.

V. vulnificus is an opportunistic pathogen of humans that causes septicemia after ingestion of contaminated oysters and

necrotizing fasciitis after contamination of wounds (reviewed in references 19 and 38). Septicemia occurs primarily in people with high levels of iron saturation caused by genetic mutation, such as primary hemochromatosis, or by liver damage (cirrhosis). Immunosuppressed individuals and people with diabetes are also at risk (4, 6, 18, 43). Septicemia is characterized by fever, chills, and bullous skin lesions on the lower extremities and has a mortality rate of greater than 50% (14). Wound infection leads to necrotizing fasciitis, which is characterized by extensive tissue damage down to, but not usually including, the musculature and can necessitate surgical intervention for debridement or amputation. Wound infection can occur in the absence of predisposing conditions but progresses more frequently to septicemia and has a higher mortality rate in predisposed people.

V. vulnificus is a halophilic, gram-negative, curved rod that thrives in tropical and temperate estuarine environments throughout the world. The bacteria are found in filter-feeding shellfish, primarily oysters. Estimates of the prevalence of *V. vulnificus* in oysters from the Gulf of Mexico during the summer months have been as high as nearly 100% (23). Bacteriophages for *V. vulnificus* also are frequently found in oysters and estuarine waters (8, 9, 27). *V. vulnificus* is highly genetically diverse, and single oysters can contain over 100 different strains (5). Despite the diversity of strains present in oysters, one study demonstrated that only single strains of *V. vulnificus* were recovered from the blood of patients who had lethal infections and who had consumed oysters contaminated with numerous strains (15), suggesting that not all strains possess equal potential for human disease.

Little is known about the virulence mechanisms of *V. vulni-*

* Corresponding author. Mailing address: Department of Molecular Genetics and Microbiology, Box 100266, College of Medicine, University of Florida, Gainesville, FL 32610-0266. Phone: (352) 392-0050. Fax: (352) 392-3133. E-mail: gulig@ufl.edu.

ficus. The primary virulence factor is the polysaccharide capsule, which prevents phagocytosis and activation of complement (1, 30, 41, 42, 45, 46), classifying *V. vulnificus* as an extracellular pathogen. The ability to acquire iron from the host via siderophore production is also an essential virulence attribute (20). The production of a prepilin peptidase of a type 2 secretion system, which exerts pleiotropic effects on numerous secreted proteins, is required for full virulence in mice (24). Two other putative virulence factors, hemolysin and metalloprotease, have failed to be confirmed as virulence factors by genetic analysis (11, 16, 29, 44), despite the fact that injection of the purified proteins into laboratory animals induces several symptoms of *V. vulnificus* infection (13, 17, 22, 25). An iron-dextran-treated mouse model of *V. vulnificus* disease was previously used to compare the virulence of three clinical isolates with that of three environmental strains isolated from oysters or seawater (37). It appeared that the environmental strains either grew more slowly in or were killed more effectively by the host.

The availability of a useful animal model to examine virulence, the existence of bacteriophages for *V. vulnificus*, and the extracellular nature of the disease process led us to use *V. vulnificus* as a model for testing the effectiveness of phage therapy for human disease. We show here that phage treatment of iron-dextran-treated mice infected subcutaneously (s.c.) with *V. vulnificus* can prevent both local and systemic disease.

(These results were presented in preliminary form at the 100th General Meeting of the American Society for Microbiology in Los Angeles, Calif. [K. E. Cervený, T. J. Doyle, G. M. Escudero, D. H. Duckworth, and P. A. Gulig, Abstr. 100th Gen. Meet. Am. Soc. Microbiol., abstr. D230, p. 279, 2000] and the 13th Annual International Phage Biology Meeting in Montreal, Quebec, Canada [K. Cervený, T. J. Doyle, A. DePaola, P. Gulig, and D. Duckworth, Abstr. Millennial Phage Biol. Meet., 2000]).

MATERIALS AND METHODS

Bacterial strains and growth media. We used four clinical isolates of *V. vulnificus*, M06-24/0, VV1009, 2400112, and NSV-5829, obtained from patients who died from sepsis following ingestion of contaminated oysters, and environmental strains MLT403, MLT365, MLT367, and 99-796DP-E7, isolated from either oysters or seawater (7, 15, 37, 40, 45). The four clinical isolates and strain 99-796DP-E7 were highly virulent in s.c. inoculated, iron-dextran-treated mice, while the environmental strains were less virulent, although still able to cause disease at higher doses (37; A. DePaola, J. L. Nordstrom, A. Dalsgaard, J. Oliver, T. Baytes, K. L. Bourdage, and P. A. Gulig, unpublished data). *V. vulnificus* strains were grown in Luria-Bertani broth containing 0.85% (wt/vol) NaCl (LB-N) or on LB-N plates containing 1.5% (wt/vol) agar. Luria-Bertani broth containing seawater (Sigma) (LB-SW) or sea salts (Sigma) adjusted to a total salt concentration of 0.85% (LB-SS) was used when sea salts were required for phage activity. Soft-agar overlays of each medium contained 0.75% (wt/vol) agar. Bacteria were grown by diluting a static overnight culture into prewarmed medium, 1:10 for phage preparations or 1:20 for the animal infections, and then shaking the mixture at 37°C until the bacteria reached approximately 10^8 CFU/ml, as determined by measuring the optical density at 600 nm. For titration of phages, bacteria were grown to a density of between 1.5×10^8 and 2.5×10^8 CFU/ml, as determined by measuring the optical density at 600 nm. Preliminary experiments demonstrated that this stage of growth allowed maximum plating efficiency of the phage. For infection of mice, cultures were grown in LB-N, harvested, and diluted in phosphate-buffered saline containing 0.01% (wt/vol) gelatin (BSG) (28) exactly as described previously (37).

Phage isolation, growth, and titration. Phage CK-2 was isolated from estuarine sediments from Cedar Key, Fla. A slurry of 50 ml of sediment and 50 ml of

LB-N was mixed with 5 ml each of LB-N cultures of *V. vulnificus* strains VV1009, LL728, 2400112, MLT403, MLT365, and MLT367. The mixture was shaken overnight at 30°C. On the next day, the mud and bacteria were removed by centrifugation at $10,000 \times g$ for 10 min, and the supernatant was filtered through a 0.2- μ m-pore-size filter. Phage activity in the supernatant was amplified by mixing with an equal volume of a static overnight culture of each of the six *V. vulnificus* strains separately and shaking the mixtures overnight at 30°C. On the next day, the cultures were centrifuged and filtered as described above, and 10 μ l of the filtrates was dropped onto LB-N agar plates seeded with a lawn of each of the bacterial strains. Plaques appeared on plates seeded with MLT403 but not with any of the other *V. vulnificus* strains. The phage from the MLT403 lysate was then plaque purified and amplified. This phage was designated CK-2. It produced very clear plaques on MLT403 grown in LB-N but had no activity on any of the other *V. vulnificus* strains that we examined.

Phages 153A-5 and 153A-7 were isolated from oysters as described previously (8, 9) and formed plaques on several of the virulent clinical strains, but phage 153A-7 formed plaques only when the vibrios were suspended in seawater-containing medium, either LB-SS or LB-SW. Broth and soft-agar lysates of these phages were produced by using strain MO6/24-0 as the host and standard procedures (28). Phages 153A-5 and 153A-7 had relatively broad host ranges, forming plaques on five of seven and seven of seven *V. vulnificus* strains tested, respectively.

Phage titers were determined in two ways: by dropping 10 μ l of a phage dilution onto a soft-agar overlay containing 10^6 CFU/ml of bacteria or by mixing a phage dilution with bacteria, adding soft agar, and pouring the mixture onto an agar plate.

Infection of mice. Seven- to 10-week-old female ICR mice (Harlan Sprague-Dawley, Indianapolis, Ind.) housed under specific-pathogen-free conditions were used for all infections. Infections were performed as described previously (37). Briefly, mice were injected intraperitoneally (i.p.) with 250 μ g of iron dextran (Sigma)/g of body weight 2 h to 30 min prior to inoculation with bacteria. Mice were injected s.c. with 0.1 ml of bacteria suspended in BSG in the lower portion of the back. Bacteriophages suspended in BSG (0.1 ml) were injected intravenously (i.v.) into the lateral tail vein at various times after bacterial inoculation. Control mice not receiving phages were injected with sterile BSG. Mice were monitored for evidence of disease by visual inspection as well as rectal temperature. Mice with temperatures of $<33^\circ\text{C}$ were considered moribund and were euthanized. Euthanasia was done by carbon dioxide asphyxiation. We measured four quantitative criteria for disease: temperature, lesion score, number of bacteria in tissues, and histologic features. Differences in quantitative analyses of infection were examined by using a two-tailed Student *t* test. All animal experiments were approved by the Institutional Animal Care and Use Committee of the University of Florida.

Temperature. The rectal temperature of the mice was recorded at the time of euthanasia to objectively quantify the state of disease. It was previously shown that the body temperature of *V. vulnificus*-infected mice significantly drops in the later stages of disease (37). If a mouse died before it could be euthanized, the temperature assigned was the lowest temperature in the surviving infected mice for the given experiment or 33°C , whichever was lowest, for the purpose of statistical analysis. For analysis of survival, a temperature of 33°C or less was scored as a death.

Lesion score. The skin was peeled back from head to tail, revealing the s.c. tissues of the back. The s.c. lesion was photographed along with a 2-cm² standard. Photographs of lesions were scored for severity in a blinded manner by using the following scale: 0, no visible change; 1, lesion with discoloration but no hemorrhage; 2, lesion with hemorrhage but smaller than 2 cm²; 3, lesion larger than 2 cm². Because lesion scores are not normally distributed, only the mean is shown, with no statistical analysis.

Quantitative analysis of bacteria in tissues. Tissue samples from s.c. lesions and from livers were removed from the mice, weighed, homogenized in 5 ml of BSG by using glass tissue homogenizers, diluted, and plated to enumerate CFU per gram of tissue. If a mouse died before it could be euthanized and examined, the presence of a typical skin lesion was visually confirmed and photographed, and the levels of tissue infection assigned were the highest levels among the surviving mice in the same group. When no bacteria were found in an undiluted sample, the minimum detectable level of infection was assigned for the purpose of statistical analysis.

Survival of mice. Survival rates for mice were calculated as a combination of actual deaths and a rectal temperature of $<33^\circ\text{C}$ at the time of euthanasia. Survival rates were examined for significance by using χ^2 analysis.

Histologic analysis. We examined the histopathologic features of a subset of the infected mice to determine whether phage therapy affected microscopic damage. Tissues of s.c. lesions were collected immediately after euthanasia, fixed




FIG. 1. Short-term protection of *V. vulnificus* MLT403-infected mice by phage CK-2. Iron-dextran-treated mice were inoculated s.c. with 10^6 CFU of *V. vulnificus* MLT403. Mice were immediately injected i.v. with BSG (C) or phage CK-2 (CK-2), and samples were harvested 14 to 18 h postinfection. Data are means and standard deviations for log CFU per gram of skin lesion (Lesion CFU), log CFU per gram of liver (Liver CFU), and rectal temperature (Temp). The temperature was divided by 10 and then plotted to fit the same scale as the other values. For lesion score (Lesion), the mean is shown. All groups contained five animals. An asterisk indicates that the difference between control and phage-treated groups was statistically significant, as determined by the Student *t* test, as follows: lesion CFU, $P = 0.016$; liver CFU, $P = 1.6 \times 10^{-4}$; temperature, $P = 7.6 \times 10^{-8}$.

in 10% (vol/vol) buffered formalin, embedded in paraffin, sectioned, mounted, and stained with hematoxylin and eosin as described previously (37).

Determination of phage half-life in mice. Uninfected mice were injected i.v. with 10^8 PFU of phage 153A-5. At 1, 6, and 12 h postinjection, mice were euthanized, and the peritoneal cavity was subjected to lavage with 4 ml of phosphate-buffered saline. The lavage fluid was collected by needle and syringe. A sample of liver was then removed, weighed, and homogenized in BSG. Finally, 10 μ l of cardiac blood was collected in 0.05 M EDTA. All of the samples were examined for PFU on *V. vulnificus* MO6/24-0 as described above.

RESULTS

Analysis of *V. vulnificus* MLT403 and phage CK-2. To examine the possible usefulness of bacteriophages in treating disease caused by *V. vulnificus*, we isolated phages which exhibited lytic activity against *V. vulnificus*. Phage CK-2 was isolated from estuarine sediments of Cedar Key, Fla., and was highly lytic, forming clear plaques on host *V. vulnificus* strain MLT403. MLT403 was the most virulent of the previously described environmental strains; however, its minimum lethal dose for iron-dextran-treated mice was 500-fold higher than that of clinically derived strains such as MO6-24/0 (37).

To determine whether phage CK-2 could protect against *V. vulnificus* infection, mice were injected i.p. with iron dextran, inoculated s.c. with 10^6 CFU (100 times the lethal dose) of MLT403, and immediately injected i.v. with 10^8 PFU of phage. Control mice were treated with iron dextran and infected with MLT403 but received BSG instead of phage. After 14 h of infection, all four of the untreated (control) mice were visibly ill, lethargic, and scruffy, with rectal temperatures ranging from 27.5 to 28.2°C (Fig. 1). All control mice had large s.c. lesions with a score of 3 (out of a maximum of 3) and with characteristic hemorrhage and edema at the site of inoculation. The control mice had a mean of 10^8 CFU/g of lesion tissue, and their livers contained a mean of nearly 10^5 CFU/g of tissue. In contrast, the four mice in the phage-treated group appeared to

be only slightly ill and had normal rectal temperatures of 36.5 to 37.6°C. Phage-treated mice euthanized at 18 h postinfection had lesions with a mean score of 2.3 and with some discoloration but little edema. Two of these mice had undetectable bacteria in their lesion samples and were assigned a minimum detectable level of log 3.2 and log 2.9 CFU/g (these numbers are different because different amounts of tissue were sampled), while the other two mice had log 7.6 and log 4.8 CFU/g of lesion tissue. For all three criteria used to measure disease, the phage-treated mice were significantly protected compared with the control mice. The survival, determined by counting either actual deaths or a temperature of $<33^\circ\text{C}$, of control mice was none of four at 18 h; in comparison, four of four phage-treated mice survived (χ^2 analysis; $P < 0.005$).

To determine whether the protection that we observed in the first experiment was only a delay in the onset of disease or whether the mice were destined to remain healthy, a long-term protection experiment was conducted. As in the first experiment, after 1 day of infection, control mice had severe lesions with high numbers of CFU in the skin and liver and depressed rectal temperatures, while phage CK-2-treated mice were significantly protected from CFU in the skin and liver (data not shown). A second set of six phage-treated mice was observed for 8 days. One of these mice died on day 5 of an unknown cause, and the remaining mice continued to appear healthy and were euthanized on day 8; no detectable bacteria were found in their skin or liver. Therefore, mice treated with CK-2 appeared to be protected from disease for the long term.

In a final set of experiments with phage CK-2, we examined how long phage treatment could be delayed without affecting its efficacy by injecting the phage 6 and 12 h after bacterial inoculation. As described above, *V. vulnificus*-infected mice were either treated with buffer (control) or 10^8 PFU of phage CK-2 at various times postinfection. Of the 10 mice in the




FIG. 2. Protection of *V. vulnificus* MO6-24/0-infected mice by phage 153A-5 but not phage 153A-7. Iron-dextran-treated mice were inoculated s.c. with 417 CFU of *V. vulnificus* MO6-24/0 and immediately injected i.v. with BSG (control) (C), phage 153A-5 (A-5S and A-5L), or phage 153A-7 (A-7S). Samples were harvested at 14 h (C, A-5S, and A-7S) or 6 days (A-5L) after infection. Data are means and standard deviations for log CFU per gram of skin lesion (Lesion CFU), log CFU per gram of liver lesion (Liver CFU), and rectal temperature (Temp). For lesion score (Lesion), the mean is shown. For the A-5L liver data, the bar represents the minimum detectable level, since no CFU were recovered. All groups contained five animals. Protection was demonstrated for A-5S Lesion CFU and Temp ($P < 0.01$) and for A-5L Lesion CFU ($P < 0.01$); marginal protection was observed for Liver CFU ($P = 0.05$). Asterisks indicate significant differences from control. Mice treated with phage 153A-7 did not show any significant protection.

control groups, only 1 survived, with a temperature of $>33^{\circ}\text{C}$. Only mice treated with phage immediately after bacterial inoculation had a 1-day survival rate significantly higher than that of their control group counterparts (four of four mice) ($P = 0.0027$). The survival rates for the 6- and 12-h treatment delay groups were three of five and one of five mice, respectively. Results for the 0-h treatment delay group were similar to those in the initial experiment; mice in the group were significantly protected in terms of all quantitative criteria ($P < 0.015$), except for liver CFU ($P = 0.07$; although there was a greater than 1,000-fold difference in CFU, the high standard deviation in the control group reduced significance). Furthermore, the 0-h treatment delay group was significantly protected in terms of all criteria compared with the 12-h treatment delay group ($P \leq 0.03$) and was significantly protected in terms of temperature compared with the 6-h treatment delay group ($P \leq 0.025$). Therefore, delays of as little as 6 h in phage treatment rendered such treatment ineffective in this model with this particular phage-host pair.

Analysis of *V. vulnificus* MO6/24-0 with two different *V. vulnificus*-specific phage. *V. vulnificus* MLT403, used in the initial experiment, is a less virulent environmental strain which requires a relatively high inoculum to cause disease (37). We therefore tested phages 153A-5 and 153A-7, which had lytic

activity against *V. vulnificus* MO6/24-0, a widely studied, highly virulent clinical isolate (16, 45). As few as 100 CFU of MO6/24-0 can cause lethal infection in s.c. inoculated, iron-dextran-treated mice (16). Phage 153A-5 was lytic for MO6/24-0 in LB-N or LB-SS (20 ppt sea salts), while phage 153A-7 required sea salts (LB-SS). We examined phage 153A-5 for its ability to protect mice from *V. vulnificus* infection and examined whether the requirement of phage 153A-7 for sea salts to lyse *V. vulnificus* would be an impediment to its effectiveness in preventing *V. vulnificus* infection in mice.

When mice were injected s.c. with 418 CFU of *V. vulnificus* MO6/24-0 and given a simultaneous i.v. injection with 10^8 PFU of phage 153A-5, significant protection was observed over a 1-day period in terms of CFU per gram of lesion and CFU per gram of liver (Fig. 2). Images of lesions from control (infected but not phage treated), phage 153A-5-treated, and phage 153A-7-treated mice are shown in Fig. 3. Phage 153A-5-treated mice had minor s.c. skin lesions at 19 h postinfection, with a mean lesion score of less than 1.5. Although body temperatures were more normal for phage 153A-5-treated mice, the differences were not statistically significant in comparison with the values for control mice. The survival rate for the phage 153A-5 group examined at 18 h (five of five mice) was significantly higher than that for the control group (two of five mice)




FIG. 3. Gross pathologic features of *V. vulnificus* MO6-24/0-infected mice treated with phages 153A-5 and 153A-7. Dorsal views of gross pathologic features of s.c. lesions caused by *V. vulnificus* MO6-24/0 in iron-dextran-treated mice from the experiment shown in Fig. 2 are presented. (A) Iron-dextran-treated mouse that was not infected. (B to E) Mice injected i.p. with iron dextran and then immediately injected s.c. in the lower right dorsal quadrant with 417 CFU of MO6-24/0. Immediately after s.c. infection, mice received an i.v. injection of sterile BSG (B), 10^8 PFU of phage 153A-7 (C and D), or 10^8 PFU of phage 153A-5 (E). Mice in panels B, C, and E were euthanized at between 14 and 20 h later, and the skin was peeled back from the head to the tail to reveal s.c. tissues. The mouse in panel D was euthanized 6 days after s.c. infection. Panels B and E reveal large, edematous, hemorrhagic lesions that have lesion scores of 3. Mice in panels C and D had lesion scores of 2.

($P = 0.038$). In contrast, sea salts-requiring phage 153A-7 did not cause significant protection in terms of any of these criteria (Fig. 2), including survival rate (two of five mice). s.c. lesions typical of untreated *V. vulnificus* infection were observed (Fig. 3).


Phage 153A-5-treated mice kept for observation for 6 days after *V. vulnificus* infection had no detectable bacteria in their livers (the minimum detectable level is shown in Fig. 2) and

had more normal temperatures, yet these were not significantly different from those for control mice at day 1 postinfection (Fig. 2). Three of the five long-term phage 153A-5-treated mice also had no detectable bacteria in their skin lesions, while the other two had various severities of skin infection. The survival rate for the long-term 153A-5-treated mice (five of five mice) was significantly higher than that for the short-term control mice ($P = 0.038$).


The presence of residual s.c. skin lesions in some of the protected 153A-5-treated mice led us to examine the histopathologic features of the lesions (Fig. 4). We observed that there was very little, if any, damage in the residual lesions in protected phage 153A-5-treated mice (Fig. 4C); however, mild inflammation was observed in treatment failures for 153A-5 (Fig. 4D). Phage 153A-7-treated mice that were not protected exhibited typical histopathologic damage that was previously described for untreated, infected mice (37) (Fig. 4B), namely, severe edema and necrosis of the dermis and s.c. tissues, with extensive infection beneath the s.c. musculature (Fig. 4E). Additionally, we occasionally observed perivascular infection in diseased 153A-7-treated mice (data not shown). Collectively, these data showed that a phage that could lyse *V. vulnificus* in LB-N could protect mice from a highly virulent strain of *V. vulnificus*, in both the short and the long terms, whereas a phage that required the presence of sea salts (LB-SS) for lytic activity failed to protect mice.

Relationship of in vitro host range to phage protection in mice. To further examine the protective abilities of phage 153A-5 and the lack of protection by phage 153A-7, we performed infections with four additional *V. vulnificus* strains. *V. vulnificus* VV1009, like MO6/24-0, is susceptible to phage 153A-5 and resistant to phage 153A-7 in LB-N but susceptible to 153A-7 in LB-SS. *V. vulnificus* 2400112, NSV-5829, and 99-796DP-E7 are resistant to phage 153A-5 in LB-N or LB-SW. When mice were infected with 398 CFU of *V. vulnificus* VV1009, simultaneously injected i.v. with 10^8 PFU of phage, and examined 1 day later, results essentially identical to those for strain MO6/24-0 were obtained (Fig. 5A). Phage 153A-5 significantly protected the mice in terms of all three criteria of disease, whereas phage 153A-7 failed to protect in terms of any of the three criteria. Additionally, the survival rate for 153A-5-treated mice (five of five) was significantly higher than ($P = 0.01$) while that for 153A-7-treated mice (two of five) was not significantly different from ($P = 0.5$) that for control mice (one of five).


To examine the specificity of protection by phage 153A-5 against *V. vulnificus* strains that were phage susceptible in vitro, we infected mice with strain 2400112, NSV-5829, or 99-796DP-E7, each of which is resistant to phage 153A-5, and treated them with 10^8 PFU of phage 153A-5. For three infections with strain 2400112, we observed sporadic, statistically significant differences in some virulence measures after phage treatment. The combined results of these experiments are shown in Fig. 5B, and the pooled results showed no significant differences in any virulence measure after phage treatment. In one infection, the liver CFU and temperature, measures of systemic disease, were statistically significantly improved by phage treatment ($P = 0.0006$ and $P = 0.0003$, respectively); however, a second repetition yielded no differences. The third infection yielded statistically significantly improved skin CFU



A




B



C



D



E

and liver CFU ($P = 0.00014$ and $P = 0.03$, respectively); however the temperatures were not statistically different between the groups in the last two infections (32 and 29°C, respectively). These low temperatures indicate that the mice were moribund. Because we observed occasional improvement in terms of various measures of virulence with phage 153-A5 treatment for strain 2400112, which is not lysed by this phage in vitro, we examined whether the bacteria might become phage susceptible during growth in the mouse host. As a surrogate, we examined the susceptibility of the bacteria to phage 153-A5 during growth in rat serum. As a positive control for phage susceptibility, strain MO6/24-0 was also examined. In both LB-N and rat serum, strain MO6/24-0 was killed by phage 153-A5, while strain 2400112 was not affected by the phage at all (data not shown).

Two infection and protection experiments each were performed with strains NSV-5829 and 99-796DP-E7 and phage 153-A5, and the combined results are shown in Fig. 5B. No statistically significant differences were observed for lesion CFU, liver CFU, or temperature with phage treatment. However, in one experiment, strain NSV-5829 produced marginally lower skin lesion CFU with phage treatment ($P = 0.03$).

Effects of delaying phage 153A-5 treatment on infection with MO6/24-0. As was attempted for phage CK-2 and *V. vulnificus* MLT403, we examined how long phage treatment could be delayed after s.c. administration of a lethal dose of *V. vulnificus* to iron-dextran-treated mice. Our failure to observe significant protection with delays of 6 and 12 h led us to examine delays of 6 h or less. Mice infected with 1,070 CFU of MO6/24-0 were injected with 10^8 PFU of phage 153A-5 at 0, 3, and 6 h postinfection and then examined for disease at day 1 postinfection. As shown in Fig. 6, all three times of administering the phage treatment resulted in significant protection in terms of all four criteria in comparison with the results for the control group. However, the numbers of CFU per gram of lesion were significantly higher for the 3- and 6-h treatment delay groups than for the 0-h treatment delay group. The numbers of CFU per gram of liver and temperature were not significantly different among the phage-treated groups. The survival rates for all phage-treated groups (five of five mice) were significantly higher than that for the control group (zero of five mice) ($P = 0.0016$). Delaying phage treatment for as long as 6 h seemed to provide protection over a short infection period of 1 day for this phage-host pair.

In a follow-up experiment, we examined whether the mice protected over a 1-day period with 6-h delayed phage treatment were destined to recover or whether the delayed phage treatment had only caused a temporary delay in lethal *V. vulnificus* infection. Seven mice were infected with *V. vulnificus* MO6/24-0 and treated with 10^8 PFU of phage 153A-5 6 h


postinfection. The experiment had to be terminated at 2 days postinfection because three mice died. One of the remaining mice had $10^{6.2}$ CFU/g of s.c. lesion, and the other three had undetectable bacteria in skin lesions. Therefore, although some longer-term protection was observed with a 6-h delayed phage treatment, the efficiency of protection was compromised compared with that obtained with simultaneous *V. vulnificus* infection and phage treatment.

Dose response in mice for phage 153A-5 protection against *V. vulnificus* MO6/24-0. Since we had been treating mice with phage 153A-5 doses of up to 10^6 -fold higher than the *V. vulnificus* inoculum, we titrated the minimum protective dose of the phage for a 1-day *V. vulnificus* infection (Fig. 7). Iron-dextran-treated mice were injected s.c. with 1,150 CFU of *V. vulnificus* MO6/24-0 and immediately injected i.v. with 10^8 , 10^6 , or 10^4 PFU of phage 153A-5. Only the highest dose of phage, 10^8 PFU, afforded significant protection to the mice in terms of every criterion. The lower doses of phage did not significantly protect the mice over the course of a 1-day infection, except for the CFU per gram of liver in the group treated with 10^6 PFU. The trends in terms of all four criteria progressed from the control group to the highest-dose phage-treated group, giving the appearance of a dose response; however, the values for the groups treated with 0, 10^4 , and 10^6 PFU were generally not significantly different from each other. The survival rate for only the group treated with 10^8 PFU (five of five mice) was significantly higher than that for the control group (one of five mice) ($P = 0.01$). The survival rate for the group treated with 10^6 PFU (four of five mice) was nearly significantly higher ($P = 0.06$). However, when similarly infected mice treated with 10^6 PFU of phage 153A-5 were monitored for 2 days, three of five mice died and a fourth had nearly 10^7 CFU/g of skin lesion (data not shown). Therefore, it appeared that very high multiplicities of phage treatment were required for significant protection against s.c. infection by *V. vulnificus* in iron-dextran-treated mice.

Half-life of phage in mouse tissues. Since delayed treatment with phages resulted in decreased efficacy of protection, we measured the stability of phage 153A-5 in mice after i.v. injection. Mice that were not infected with *V. vulnificus* were injected i.v. with 10^8 PFU of phage, and the numbers of phage were measured in the blood, liver, and peritoneal fluid. From 1 h postinjection to 12 h postinjection, the PFU per milliliter of blood dropped over 43-fold from $10^{6.4}$ to $10^{4.9}$ PFU/ml, yielding a half-life of 2.2 h (Fig. 8). The PFU per gram of liver was approximately 10% the PFU per milliliter of blood at 1 h postinjection, and liver PFU dropped only 10-fold over the course of the experiment. The ability of the i.v. injected phage to translocate out of the vasculature into the peritoneal cavity was very low. At 1 h postinjection, only about 0.1% the dose of

FIG. 4. Histopathologic features of mice infected with MO6-24/0 and treated with phages 153A-5 and 153A-7. The micrographs depict the histologic features of the mice from the experiment shown in Fig. 3. (A) Healthy mouse that received only an i.p. injection of iron. (B to E) Mice injected s.c. with 417 CFU of MO6-24/0. Tissues were collected from each mouse at death, fixed in buffered formalin, embedded in paraffin, and cut into 5- μ m sections. Sections were stained with hematoxylin and eosin and observed at a magnification of $\times 200$. (B) Control mouse (*V. vulnificus* infected, not phage treated). Necrosis and edema in the dermis (d) and subcutis (s) are indicated. (C) Phage 153A-5-treated mouse with no histologic damage. (D) Failure of phage 153A-5 treatment, with a lesion score of 2. The dermis and subcutis are intact, but inflammation (i) is indicated. (E) Failure of phage 153A-7 treatment. Necrosis in the dermis (d) and subcutis and edema were observed.

A



B




FIG. 5. Analysis of protection of mice by phage 153A-5 with additional *V. vulnificus* strains. VV1009 is phage susceptible and 2400112, NSV-5829, and 99-796DP-E7 are phage resistant in vitro. (A) Iron-dextran-treated mice were inoculated s.c. with 398 CFU of *V. vulnificus* VV1009. Mice were injected i.v. with BSG (control) (C), phage 153A-5 (A-5), or phage 153A-7 (A-7) immediately after s.c. infection. Samples were harvested at 14 h. Data are means and standard deviations for log CFU per gram of skin lesion (Lesion CFU), log CFU per gram of liver lesion (Liver CFU), and rectal temperature (Temp). For lesion score (Lesion), the mean is shown. All groups contained five animals. Protection was observed for Lesion CFU, Liver CFU, and Temp (A-5) ($P < 0.02$ [compared to control]). Asterisks indicate significant differences from control. Phage 153A-7-treated mice were not protected in terms of any criteria. (B) Iron-dextran-treated mice were inoculated s.c. with approximately 1,000 CFU of *V. vulnificus* 2400112 (bars with vertical lines), NSV-5829 (NSV; bars with stippling), or 99-796DP-E7 (99-796; bars with horizontal lines). Mice were injected i.v. with BSG (control) (white background) or phage 153A-5 (grey background) immediately after s.c. infection. Samples were harvested 15 to 20 h later. Data are means and standard deviations for log CFU per gram of skin lesion (Lesion CFU), log CFU per gram of liver lesion (Liver CFU), and rectal temperature (Temp). Data represent two or three combined experiments. Numbers of animals in groups were as follows: for 2400112, without phage, $n = 15$, and with phage, $n = 16$; for NSV-5829, with or without phage, $n = 15$; and for 99-796DP-E7, without phage, $n = 10$, and with phage, $n = 8$. No significant differences were observed with phage treatment in the pooled results for any strain; however, some individual experiments for some strains yielded statistically significant differences (see the text).




FIG. 6. Delay of phage 153A-5 treatment of *V. vulnificus* MO6-24/0-infected mice. Iron-dextran-treated mice were inoculated s.c. with 1,070 CFU of *V. vulnificus* MO6-24/0. Mice were injected i.v. with BSG (control) (C) immediately or with 10^8 PFU of phage 153A-5 immediately (0), 3 h later (3), or 6 h later (6). Samples were harvested 14 h after s.c. inoculation. Data are means and standard deviations for log CFU per gram of skin lesion (Lesion CFU), log CFU per gram of liver lesion (Liver CFU), and rectal temperature (Temp). For lesion score (Lesion), the mean is shown. All groups contained five animals. Single asterisks indicate that values for the control group were significantly different from those for all of the phage-treated groups ($10^{-9} < P < 0.013$). Double asterisks indicate that the 0-h treatment delay group was significantly protected compared with the 3- and 6-h treatment delay groups ($6 \times 10^{-6} < P < 0.0035$).

injected phage was recovered from the peritoneal lavage fluid, and the level dropped less than 10-fold over the 12-h period. i.v. injected phage 153A-5 appeared to be relatively stable in blood, yet it was unable to escape the vasculature into the tissues of these animals not infected with *V. vulnificus*.

DISCUSSION

To examine the feasibility, kinetics, and limitations of phage therapy, we used a mouse model of *V. vulnificus* infection. We show that it is possible to prevent both local and systemic




FIG. 7. Titration of phage 153A-5 in *V. vulnificus* MO6-24/0-infected mice. Iron-dextran-treated mice were inoculated s.c. with 1,150 CFU of *V. vulnificus* MO6-24/0. Mice were injected i.v. with BSG (control) (-) or with 10^8 PFU (8), 10^6 PFU (6), or 10^4 PFU (4) of phage 153A-5 immediately after s.c. infection. Samples were harvested 14 to 20 h later. Data are means and standard deviations for log CFU per gram of skin lesion (Lesion CFU), log CFU per gram of liver lesion (Liver CFU), and rectal temperature (Temp). For lesion score (Lesion), the mean is shown. Single asterisks indicated that values for the phage-treated group were significantly different from those for the control group ($2.5 \times 10^{-5} < P < 0.02$). Double asterisks indicate that values for the 10^8 PFU-treated group were significantly different from those for the 10^6 or 10^4 PFU-treated group ($P < 0.02$).




FIG. 8. Half-life of phages in mouse tissues. Mice were treated with iron dextran but not s.c. infected with *V. vulnificus*. Phage 153A-5 was injected i.v. at 10^8 PFU per mouse. Samples of the blood, liver, and peritoneal lavage fluid were sampled at 1, 6, and 12 h after injection of the phage, and numbers of PFU per milliliter or PFU per gram of tissue were enumerated. The half-life of the phage in the blood was calculated to be 2.2 h. Data are means and standard deviations.

disease caused by *V. vulnificus* in an iron-dextran-treated mouse model by administering bacteriophages that are lytic for the infecting bacterial strain. Phage CK-2 could prevent infection by *V. vulnificus* MLT403, and phage 153A-5 could prevent infection by *V. vulnificus* MO6/24-0 and VV1009. We quantitatively measured disease and protection by using four criteria: s.c. lesion score and CFU per gram of s.c. lesion as measures of local disease and body temperature and CFU per gram of liver as measures of systemic disease. We also measured the survival of mice. In most, but not all, treated mice, these phages could significantly reduce these measures of disease and in many instances resulted in apparently sterile lesions and livers. Achievement of this level of protection required the administration of high doses of phage (10^8 PFU/mouse) relatively soon after inoculation.

We hypothesize the phage-bacterium interaction in this mouse model for *V. vulnificus* disease to be follows. After s.c. inoculation into iron-dextran-treated mice, the vibrios begin to replicate at an extremely rapid rate. In the initial characterization of this model, the slowest doubling time of the bacteria in the mice was calculated to be 45 min (37). Although the vibrios and phages are often administered to mice simultaneously, they may not come into contact until some time after injection. Early on, the vibrios may be sequestered in the intercellular fluid in the s.c. tissues, while the phages are present in the bloodstream. Particles as large as phages may not freely pass through the vascular endothelium. The very small amounts of phages obtained from the peritoneal lavage fluid over a 12-h time course are in agreement with this hypothesis. However, as the vibrios reach sufficient numbers in the tissues, they induce vasodilation and vascular permeability (3), thereby enabling the phages access to the bacteria as edema floods the infected tissues. Therefore, the bacteria may actually induce their own demise in this particular model system. The fact that phages

administered i.v. can be effective at clearing local infection of the skin tissues suggests that such treatment may be useful in a clinical setting for *V. vulnificus* disease, where i.v. administration would be most efficient at delivering the phages throughout the body.

With regard to the mechanism whereby phages elicit their protective effect, we have shown that it is, as expected, killing of the bacteria. We generally did not observe protection when the chosen phage was unable to lyse the inoculating *V. vulnificus* strain in vitro. This relationship was shown in two ways. First, we noted that phage 153A-7 formed plaques on the host bacteria only when bacterial medium containing sea salts or seawater was used. Since these conditions are not present in animals, such phages should not be able to lyse the bacteria in the infected animal host. We demonstrated that phage 153A-7 failed to protect mice from infection with *V. vulnificus* MO6/24-0 (Fig. 2) and VV1009 (Fig. 5). There are at least two possible reasons for the failure of phage 153A-7 to form plaques on *V. vulnificus* in the absence of sea salts. Either the receptor on *V. vulnificus* cells is not expressed in the absence of sea salts or the salts are required for the binding of the phage to the receptor. We have yet to examine these possibilities. Clearly, phages such as phage 153A-7 would not be clinically useful.

A second reason that phages failed to form plaques was the limited host range for the *V. vulnificus* strains in any media tested. We would not expect these phage-bacterium mixtures to yield protection in our mouse model. As shown in Fig. 5B, phage 153A-5 failed to consistently protect mice from s.c. infection with *V. vulnificus* 2400112, NSV-5829, and 99-796DP-E7, which were resistant to 153A-5. Figure 5B depicts the combined results of three experiments for strain 2400112 and two experiments for NSV-5829 and 99-796DP-E7 because it was noted that for strains 2400112 and NSV-5829, various measures of virulence were sporadically significantly ameliorated by phage treatment. The occasional statistically significant differences were not nearly on the same order as those seen with the productive phage-host strain combinations, in which the mice were completely protected. These statistically significant differences for the apparently resistant *V. vulnificus* strains were of questionable biological significance. The reason for these sporadic differences in the absence of in vitro plaque-forming activity of the phage is unknown. One possibility is that the phage is able to infect and kill or debilitate the bacteria without releasing enough progeny phage to form a plaque in vitro. In this scenario, the phage in the bloodstream of the mice would be able to kill vibrios that leak into the vasculature as the disease progresses in the skin. However, we found that strain 2400112 was not killed by phage 153-A5 in either LB-N or rat serum. It is also possible that residual bacterial components in the phage lysates, e.g., lipopolysaccharide, induced an inflammatory response upon i.v. injection and that this inflammatory response slightly boosted the resistance of the mice to infection. However, such a phenomenon was not always apparent, because phage 153-A7, which could lyse its host bacteria only in the presence of seawater, offered no such protection.

To examine the limitations of our phage therapy model, we either delayed treatment with phages after bacterial infection or titrated the minimum numbers of phages required for pro-

tection. As shown in Fig. 6, delaying phage treatment for more than 3 h resulted in failure. Even though mice were significantly protected at 1 day postinfection, many became ill within 2 days. The reason for the inability to confer protection after delayed treatment in our model is unknown. The progression of disease in our model is extremely rapid, with death occurring as soon as 12 h after infection with a minimum lethal dose. Since the histopathologic features of the s.c. lesions consist of thrombosis of capillaries (37), it is possible that with delayed phage treatment, the localized vasculature is clotted off, thereby preventing the entry of subsequently administered phages into the infected tissues. In contrast, when the phages are present early during the infection, they may leak into the infected tissues before thrombosis occurs and begin to kill and replicate in the infecting vibrios. Another possibility is that the numbers of bacteria have increased to such a high level that the phages cannot kill them all. Figure 7 shows that a high level of phage, i.e., 10^8 PFU, is required to protect against a minimum lethal dose of bacteria, and the half-life of phage 153A-5 in mice is approximately 2.2 h. It therefore appears that the phages are relatively stable in mouse fluids, particularly the vasculature. The reason for the ineffectiveness of lower doses of the phages is unknown. However, very high levels of phages do not appear to have harmful side effects.

Phage therapy has been widely used in Eastern Europe for many decades, and animal model studies have been investigated in the West since the early 1980s (10, 39). Almost all of these studies have shown that phage therapy has great potential, but more research needs to be done to understand the parameters that limit the effectiveness of phage therapy in different diseases. Phages have some unique advantageous features that could make them highly efficacious under certain conditions. (i) Phages are capable of replicating in a treated patient by infecting the bacteria, with the subsequent release of 100-fold more phage. This effect is in marked contrast to that of antibiotics, which only decrease in concentration from the time when they are administered. (ii) Phages are specific to bacterial species; hence, the normal microbial flora will be preserved. In contrast, the use of many antibiotics disrupts the normal flora, a process which may lead to secondary symptoms. (iii) Phages can be isolated that recognize virulence factors as receptors so that phage-resistant mutants that have lost their receptors will be attenuated. (iv) Because of their specificity to bacteria, phages have very few, if any, side effects in the treated patient. Many antibiotics exert toxic side effects. (v) Phages can be used topically as well as in the environment to control populations of bacterial pathogens. In spite of these advantages, phage therapy also has its drawbacks. The specificity of phages for host bacteria necessitates the use of broad-host-range phages or pools of phages with broad collective activity or at least the identification of phages with activity against the infecting bacterial strains. Bacteria can become resistant to phages by spontaneous mutation. In theory, the production of antiphage antibodies by phage-treated hosts could interfere with subsequent treatments with the same phage. Finally, in our experimental system, high numbers of phages needed to be administered soon after bacterial infection for treatment to be effective. Optimizing the beneficial attributes of phage therapy while decreasing the potential problems will require continuing analysis of animal models of infection.

In summary, our results demonstrate that treatment of *V. vulnificus*-infected mice can prevent local and systemic disease as well as death. These results contribute to the growing body of evidence that phage therapy is a viable alternative treatment modality for bacterial infectious disease. Our *V. vulnificus* phage therapy model will now be used to define the major benefits and limitations of phage therapy.

ACKNOWLEDGMENTS

This work was supported by Department of Commerce sea grant R/LR-Q-20 to D.H.D. and P.A.G. and a focused giving award from Johnson and Johnson, Inc., to P.A.G.

We thank Anita C. Wright for review of the manuscript and Thomas J. Doyle, Julio Martin, and Eric Wilkening for expert technical assistance.

REFERENCES

- Amako, K., K. Okada, and S. Miake. 1984. Evidence for the presence of a capsule in *Vibrio vulnificus*. *J. Gen. Microbiol.* **130**:2741–2743.
- Berchieri, A., M. A. Lovell, and P. A. Barrow. 1991. The activity in the chicken alimentary tract of bacteriophages lytic for *Salmonella typhimurium*. *Res. Microbiol.* **142**:541–549.
- Bowdre, J. H., M. D. Poole, and J. D. Oliver. 1981. Edema and hemoconcentration in mice experimentally infected with *Vibrio vulnificus*. *Infect. Immun.* **32**:1193–1199.
- Brennt, C. E., A. C. Wright, S. K. Dutta, and J. G. Morris, Jr. 1991. Growth of *Vibrio vulnificus* in serum from alcoholics: association with high transferrin iron saturation. *J. Infect. Dis.* **164**:1030–1032.
- Buchrieser, C., V. V. Gangar, R. L. Murphree, M. L. Tamplin, and C. W. Kaspar. 1995. Multiple *Vibrio vulnificus* strains in oysters as demonstrated by clamped homogeneous electric field gel electrophoresis. *Appl. Environ. Microbiol.* **61**:1163–1168.
- Bullen, J. J., P. B. Spalding, C. G. Ward, and J. M. Gutteridge. 1991. Hemochromatosis, iron and septicemia caused by *Vibrio vulnificus*. *Arch. Intern. Med.* **151**:1606–1609.
- Cook, D. W., P. O'Leary, J. C. Hunsucker, E. M. Sloan, J. C. Bowers, R. J. Blodgett, and A. DePaola. 2002. *Vibrio vulnificus* and *Vibrio parahaemolyticus* in U.S. retail shell oysters: a national survey from June 1998 to July 1999. *J. Food Prot.* **65**:79–87.
- DePaola, A., S. McLeroy, and G. McManus. 1997. Distribution of *Vibrio vulnificus* phage in oyster tissues and other estuarine habitats. *Appl. Environ. Microbiol.* **63**:2464–2467.
- DePaola, A., M. L. Motes, A. M. Chan, and C. A. Suttle. 1998. Phages infecting *Vibrio vulnificus* are abundant and diverse in oysters (*Crassostrea virginica*) collected from the Gulf of Mexico. *Appl. Environ. Microbiol.* **64**:346–351.
- Duckworth, D. H., and P. A. Gulig. 2001. Bacteriophages: potential treatment for bacterial infections. *BioDrugs* **16**:57–62.
- Fan, J. J., C. P. Shao, Y. C. Ho, C. K. Yu, and L. I. Hor. 2001. Isolation and characterization of a *Vibrio vulnificus* mutant deficient in both extracellular metalloprotease and cytotoxin. *Infect. Immun.* **69**:5943–5948.
- Flaherty, J. E., J. B. Jones, B. K. Harbaugh, G. C. Somodi, and L. E. Jackson. 2000. Control of bacterial spot on tomato in the greenhouse and field with H-mutant bacteriophages. *Hortscience* **35**:882–884.
- Gray, L. D., and A. S. Kreger. 1985. Purification and characterization of an extracellular cytotoxin produced by *Vibrio vulnificus*. *Infect. Immun.* **48**:62–72.
- Hlady, W. G., and K. C. Klontz. 1996. The epidemiology of *Vibrio* infections in Florida, 1981–1993. *J. Infect. Dis.* **173**:1176–1183.
- Jackson, J. K., R. L. Murphree, and M. L. Tamplin. 1997. Evidence that mortality from *Vibrio vulnificus* infection results from single strains among heterogeneous populations in shellfish. *J. Clin. Microbiol.* **35**:2098–2101.
- Jeong, K. C., H. S. Jeong, J. H. Rhee, S. E. Lee, S. S. Chung, A. M. Starks, G. M. Escudero, P. A. Gulig, and S. H. Choi. 2000. Construction and phenotypic evaluation of a *Vibrio vulnificus* *vvpE* mutant for elastolytic protease. *Infect. Immun.* **68**:5096–5106.
- Kook, H., S. E. Lee, Y. H. Baik, S. S. Chung, and J. H. Rhee. 1996. *Vibrio vulnificus* hemolysin dilates rat thoracic aorta by activating guanylate cyclase. *Life Sci.* **59**:PL41–PL47.
- Kraffert, C. A., and D. J. Hogan. 1992. *Vibrio vulnificus* infection and iron overload. *J. Am. Acad. Dermatol.* **26**:140.
- Linkous, D. A., and J. D. Oliver. 1999. Pathogenesis of *Vibrio vulnificus*. *FEMS Microbiol. Lett.* **174**:207–214.
- Litwin, C. M., T. W. Rayback, and J. Skinner. 1996. Role of catechol siderophore synthesis in *Vibrio vulnificus* virulence. *Infect. Immun.* **64**:2834–2838.
- Merrill, C. R., B. Biswas, R. Carlton, N. C. Jensen, G. J. Creed, S. Zullo, and

- S. Adhya. 1996. Long-circulating bacteriophage as antibacterial agents. Proc. Natl. Acad. Sci. USA **93**:3188–3192.
22. Miyoshi, S., and S. Shinoda. 1988. Role of the protease in the permeability enhancement by *Vibrio vulnificus*. Microbiol. Immunol. **32**:1025–1032.
 23. Motes, M. L., A. DePaola, D. W. Cook, J. E. Veazey, J. C. Hunsucker, W. E. Garthright, R. J. Blodgett, and S. J. Chirtel. 1998. Influence of water temperature and salinity on *Vibrio vulnificus* in Northern Gulf and Atlantic Coast oysters (*Crassostrea virginica*). Appl. Environ. Microbiol. **64**:1459–1465.
 24. Paranjpye, R. N., J. C. Lara, J. C. Pepe, C. M. Pepe, and M. S. Strom. 1998. The type IV leader peptidase/N-methyltransferase of *Vibrio vulnificus* controls factors required for adherence to HEp-2 cells and virulence in iron-overloaded mice. Infect. Immun. **66**:5659–5668.
 25. Park, J. W., S. N. Ma, E. S. Song, C. H. Song, M. R. Chae, B. H. Park, R. W. Rho, S. D. Park, and H. R. Kim. 1996. Pulmonary damage by *Vibrio vulnificus* cytotoxin. Infect. Immun. **64**:2873–2876.
 26. Park, S. C., I. Shimamura, M. Fukunaga, K. I. Mori, and T. Nakai. 2000. Isolation of bacteriophages specific to a fish pathogen, *Pseudomonas plecoglossicida*, as a candidate for disease control. Appl. Environ. Microbiol. **66**:1416–1422.
 27. Pelon, W., R. J. Siebeling, J. Simonson, and R. B. Luftig. 1995. Isolation of bacteriophage infectious for *Vibrio vulnificus*. Curr. Microbiol. **30**:331–336.
 28. Provence, D. L., and R. Curtiss III. 1994. Gene transfer in gram-negative bacteria, p. 317–347. In P. Gerhardt, R. G. E. Murray, W. A. Wood, and N. R. Krieg (ed.), Methods for general and molecular bacteriology. American Society for Microbiology, Washington, D.C.
 29. Shao, C. P., and L. I. Hor. 2000. Metalloprotease is not essential for *Vibrio vulnificus* virulence in mice. Infect. Immun. **68**:3569–3573.
 30. Shinoda, S., M. Kobayashi, H. Yamada, S. Yoshida, M. Ogawa, and Y. Mizuguchi. 1987. Inhibitory effect of capsular antigen of *Vibrio vulnificus* on bactericidal activity of human serum. Microbiol. Immunol. **31**:393–401.
 31. Smith, H. W., and M. B. Huggins. 1982. Successful treatment of experimental *Escherichia coli* infections in mice using phage: its general superiority over antibiotics. J. Gen. Microbiol. **128**:307–318.
 32. Smith, H. W., and M. B. Huggins. 1983. Effectiveness of phages in treating experimental *Escherichia coli* diarrhoea in calves, piglets and lambs. J. Gen. Microbiol. **129**:2659–2675.
 33. Smith, H. W., M. B. Huggins, and K. M. Shaw. 1987. Factors influencing the survival and multiplication of bacteriophages in calves and in their environment. J. Gen. Microbiol. **133**:1127–1135.
 34. Smith, H. W., M. B. Huggins, and K. M. Shaw. 1987. The control of experimental *Escherichia coli* diarrhoea in calves by means of bacteriophages. J. Gen. Microbiol. **133**:1111–1126.
 35. Soothill, J. S. 1992. Treatment of experimental infections of mice with bacteriophages. J. Med. Microbiol. **37**:258–261.
 36. Soothill, J. S. 1994. Bacteriophage prevents destruction of skin grafts by *Pseudomonas aeruginosa*. Burns **20**:209–211.
 37. Starks, A. M., T. R. Schoeb, M. L. Tamplin, S. Parveen, T. J. Doyle, P. E. Bomeisl, G. M. Escudero, and P. A. Gulig. 2000. Pathogenesis of infection by clinical and environmental strains of *Vibrio vulnificus* in iron-dextran-treated mice. Infect. Immun. **68**:5785–5793.
 38. Strom, M. S., and R. N. Paranjpye. 2000. Epidemiology and pathogenesis of *Vibrio vulnificus*. Microbes Infect. **2**:177–188.
 39. Sulakvelidze, A., Z. Alavidze, and J. G. Morris. 2001. Bacteriophage therapy. Antimicrob. Agents Chemother. **45**:649–659.
 40. Tamplin, M. L., J. K. Jackson, C. Buchrieser, R. L. Murphree, K. M. Portier, V. Gangar, L. G. Miller, and C. W. Kaspar. 1996. Pulsed-field gel electrophoresis and ribotype profiles of clinical and environmental *Vibrio vulnificus* isolates. Appl. Environ. Microbiol. **62**:3572–3580.
 41. Tamplin, M. L., S. Specter, G. E. Rodrick, and H. Friedman. 1983. Differential complement activation and susceptibility to human serum bactericidal action by *Vibrio* species. Infect. Immun. **42**:1187–1190.
 42. Tamplin, M. L., S. Specter, G. E. Rodrick, and H. Friedman. 1985. *Vibrio vulnificus* resists phagocytosis in the absence of serum opsonins. Infect. Immun. **49**:715–718.
 43. Vollberg, C. M., and J. L. Herrera. 1997. *Vibrio vulnificus* infection: an important cause of septicemia in patients with cirrhosis. South. Med. J. **90**:1040–1042.
 44. Wright, A. C., and J. G. Morris, Jr. 1991. The extracellular cytotoxin of *Vibrio vulnificus*: inactivation and relationship to virulence in mice. Infect. Immun. **59**:192–197.
 45. Wright, A. C., L. M. Simpson, J. D. Oliver, and J. G. Morris, Jr. 1990. Phenotypic evaluation of acapsular transposon mutants of *Vibrio vulnificus*. Infect. Immun. **58**:1769–1773.
 46. Yoshida, S., M. Ogawa, and Y. Mizuguchi. 1985. Relation of capsular materials and colony opacity to virulence of *Vibrio vulnificus*. Infect. Immun. **47**:446–451.

Editor: J. T. Barbieri